Dual HER2 inhibition and pathological complete response in early breast cancer: increasing success of treatment by improving patient selection.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Annals of Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdx016PMID 28426119
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

  2016cited by this paper
• Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.

  2016cited by this paper
• Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

  2014cited by this paper
• Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).

  2013cited by this paper
• Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

  2012cited by this paper
• Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

  2012cited by this paper
• Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40)

  2012cited by this paper

• The prognostic potential of mammographic growth rate of invasive breast cancer in the Nijmegen breast cancer screening cohort

  2024cites this paper
• PARP inhibitor combinations with high-dose vitamin C in the treatment of Ewing sarcoma: two case reports and mechanistic overview

  2023cites this paper
• Estrogenicity of essential oils is not required to relieve symptoms of urogenital atrophy in breast cancer survivors

  2018cites this paper
• An inter-observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish breast cancer cooperative group (DBCG)

  2018cites this paper
• Real-time navigation system for sentinel lymph node biopsy in breast cancer patients using projection mapping with indocyanine green fluorescence

  2018cites this paper
• Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration

  2018cites this paper
• Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials

  2018cites this paper
• The occurrence of fractures after adjuvant treatment of breast cancer: a DBCG register study

  2018cites this paper
• Molecular subtypes of screen-detected breast cancer

  2018cites this paper
• Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era

  2018cites this paper
• Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator study

  2018cites this paper
• The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017: Egyptian view

  2018cites this paper
• HER1-based vaccine: Simultaneous activation of humoral and cellular immune response.

  2018cites this paper
• Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists

  2018cites this paper
• Optimal management of luminal breast cancer: how much endocrine therapy is long enough?

  2018cites this paper
• De-escalation of breast radiotherapy after conserving surgery in low-risk early breast cancer patients

  2018cites this paper
• Advances in targeting HER2-positive breast cancer

  2017cites this paper